A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer
Abstract
Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 5 subjects at WCMC. An additional 33 subjects enrolled (28 treated) at participating sub-sites. Reports submitted to WCMC DSMB in July 2014 with approval to proceed without modifications.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2014
- Accession Number
- ADA621020
Entities
People
- Scott T Tagawa
Organizations
- Cornell University